Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme Reports Q3 2026 Results with 39% Total Revenue Growth and Raises Full-Year Guidance

Positive Impact 4 of 5 earnings

Halozyme Therapeutics reported third quarter 2026 total revenue of $493 million, representing a 39% increase year-over-year, alongside net income of $247 million. Driven by strong partner product sales and royalty growth, the company raised its full-year 2026 financial guidance ranges for total revenue, royalty revenue, adjusted EBITDA, and non-GAAP diluted EPS.

Key points

  • Total revenue increased 39% year-over-year to $493 million for the third quarter ended September 30, 2026.
  • Royalty revenue grew 44% year-over-year to $341 million.
  • Full-year 2026 total revenue guidance was raised to a range of $1.860 billion to $1.925 billion.
  • The Dutch patent court issued an injunction against Merck prohibiting the launch of Keytruda Qlex in multiple European markets.

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:08 PM ET
Accession number0001159036-26-000143

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 6, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.